Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health Care Utilization in Adults With Congenital Heart Disease: Population-Based Findings.

Birth defects research·2026
Same author

Population Pharmacokinetics and Exposure-Safety Analysis of Furosemide in Preterm Infants.

Journal of clinical pharmacology·2026
Same author

The Feasibility of Using Best Practice Alerts in Pediatric Primary Care for Obesity Research.

Academic pediatrics·2026
Same author

Evaluating the duration of post-discontinuation therapeutic ampicillin exposures in preterm infants.

Journal of perinatology : official journal of the California Perinatal Association·2026
Same author

Association of Material Hardship and Clinical Outcomes in Infants with Congenital Heart Disease.

Pediatric cardiology·2026
Same author

Population Pharmacokinetics to Support Intravenous and Enteral Methadone Dosing in Children.

Journal of clinical pharmacology·2025

Related Experiment Video

Updated: Jun 5, 2026

Pediatric Animal Model of Extracorporeal Cardiopulmonary Resuscitation After Prolonged Circulatory Arrest
04:55

Pediatric Animal Model of Extracorporeal Cardiopulmonary Resuscitation After Prolonged Circulatory Arrest

Published on: May 26, 2023

Pediatric cardiovascular drug trials, lessons learned.

Jennifer S Li1, Michael Cohen-Wolkowiez, Sara K Pasquali

  • 1Department of Pediatrics and Duke Clinical Research Institute, Durham, NC, USA. jennifer.li@duke.edu

Journal of Cardiovascular Pharmacology
|January 19, 2011
PubMed
Summary

Pediatric cardiovascular drug trials face challenges, often failing to show efficacy or dose response in children. Lessons learned from these trials can improve future pediatric clinical trial design and drug development.

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Related Experiment Videos

Last Updated: Jun 5, 2026

Pediatric Animal Model of Extracorporeal Cardiopulmonary Resuscitation After Prolonged Circulatory Arrest
04:55

Pediatric Animal Model of Extracorporeal Cardiopulmonary Resuscitation After Prolonged Circulatory Arrest

Published on: May 26, 2023

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Area of Science:

  • Pediatric Cardiology
  • Clinical Pharmacology
  • Drug Development

Background:

  • Limited FDA-approved cardiovascular drugs for pediatric use necessitate off-label prescribing.
  • Increasing pediatric cardiology trials aim to address this gap.
  • Many trials show inconsistent efficacy or dose-response relationships in children compared to adults.

Purpose of the Study:

  • To identify challenges and lessons learned from pediatric cardiovascular clinical trials.
  • To inform future trial design for pediatric cardiovascular drug development.

Main Methods:

  • Analysis of factors contributing to difficulties and failures in pediatric cardiovascular trials.
  • Review of common issues including formulation, pharmacokinetics, dosing, equipoise, and endpoints.

Main Results:

  • Lack of liquid formulations and inadequate pharmacokinetic data hinder trial design.
  • Poor dose selection and lack of clinical equipoise present significant hurdles.
  • Use of surrogate and composite endpoints complicates efficacy assessment.

Conclusions:

  • Several factors contribute to the challenges and failures in pediatric cardiovascular trials.
  • Understanding these challenges is crucial for improving future pediatric drug development and trial design.